The overall goal of the Fermentation Shared Facility is to generate cells and biologic materials which will expedite research efforts of Cancer Center members. The Fermentation Shared Facility provides members of the Comprehensive Cancer with the capability to produce microbial, animal and insect cells and their products on a scale that would be uneconomic in the laboratory. The facility consists of space with equipment for large-scale cell growth, for cell disruption, for bioprocessing (purification) and for appropriate analytical measurements. The scale for cell growth ranges from eight to four hundred liters, whereas that for cell disruption changes from one hundred millimeters to forty liters. In addition the facility makes available biomass of several stock strains of bacteria, one strain of animal cells and two proteins. The facility also makes available significant expertise in the production and purification of biological material. From October 1, 1997 to September 30, 1998, the facility provided 128 units of use by members of the Center for fermentation and bioprocessing. The facility was used by 14 principle investigations with 17 funded projects. Their use was instrumental in 29 publications. The usage of the Fermentation Shared Facility increased for the first 12 years of operation and now has apparently reached somewhat of a constant usage rate.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013148-29
Application #
6319475
Study Section
Subcommittee G - Education (NCI)
Project Start
1985-07-01
Project End
2005-02-28
Budget Start
Budget End
Support Year
29
Fiscal Year
2000
Total Cost
$195,927
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Geng, Mengxin; Austin, Frank; Shin, Ronald et al. (2018) Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2. Appl Environ Microbiol 84:
Samykutty, Abhilash; Grizzle, William E; Fouts, Benjamin L et al. (2018) Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 182:114-126
Friedman, Gregory K; Bernstock, Joshua D; Chen, Dongquan et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep 8:13930
Powell, T Clark; Dilley, Sarah E; Bae, Sejong et al. (2018) The Impact of Racial, Geographic, and Socioeconomic Risk Factors on the Development of Advanced-Stage Cervical Cancer. J Low Genit Tract Dis 22:269-273
Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913
Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Fancy, Romone M; Kim, Harrison; Napier, Tiara et al. (2018) Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem 119:6216-6230

Showing the most recent 10 out of 747 publications